{"id":14882,"date":"2020-01-02T07:06:11","date_gmt":"2020-01-02T12:06:11","guid":{"rendered":"https:\/\/medicarereport.org\/?p=14882"},"modified":"2020-01-02T07:06:11","modified_gmt":"2020-01-02T12:06:11","slug":"3-drug-pricing-policy-experiments-to-watch-in-2020","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=14882","title":{"rendered":"3 drug pricing policy experiments to watch in 2020"},"content":{"rendered":"<p>(By Nicholas Florko for ST<em>A<\/em>T)<\/p>\n<p>WASHINGTON \u2014 Politicians spent the better part of 2019 bickering over the best way to lower drug prices. But in the meantime, states, advocates \u2014 even the drug and insurance industries \u2014 were devising novel strategies for solving this perplexing challenge.\u00a0 Continue reading article <a href=\"https:\/\/www.statnews.com\/2020\/01\/02\/3-drug-pricing-policy-experiments-to-watch-in-2020\/\">here&#8230;<\/a><\/p>\n<p><a href=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-4372\" src=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png\" alt=\"\" width=\"300\" height=\"32\" srcset=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png 300w, https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png 453w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><\/p>\n<pre><strong>Notice:<\/strong> The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.<\/pre>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>(By Nicholas Florko for STAT) WASHINGTON \u2014 Politicians spent the better part of 2019 bickering over the best way to<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20,10,15],"tags":[],"class_list":["post-14882","post","type-post","status-publish","format-standard","hentry","category-health-care-redesign","category-legislative-update","category-part-dprescription-drugs"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/14882","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=14882"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/14882\/revisions"}],"predecessor-version":[{"id":14883,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/14882\/revisions\/14883"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=14882"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=14882"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=14882"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}